ClinicalTrials.gg
Not yet recruitingNCT07857109Updated Oct 5, 2026

Low-Intensity Focused Ultrasound Targeting the Dorsolateral Prefrontal Cortex for Preventive Treatment of Chronic Migraine

An interventional study of Low-Intensity Focused Ultrasound Stimulation and Sham Low-Intensity Focused Ultrasound Stimulation in Chronic Migraine Headache, sponsored by Chinese PLA General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Planned enrollment
57th of 61
36 · median 288
Started
2026
with 9 others
No phase
21 of 80
12 open now
Primary completion
2027-12
later than 26 of 39 live
Registered
78th of 80
by date
Lead sponsor
3 of 80
Chinese PLA General Hospital

Among the 80 studies in Migraine Disorders with a site in China, this one is the 57th largest by planned enrollment of the 61 interventional ones that give a count, is one of 10 that started in 2026, is one of 21 with no phase, reaches primary completion later than 26 of the 39 other live ones, and was the 78th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

Chronic migraine is a disabling neurological disorder characterized by frequent headache attacks and significant impairment of quality of life. Low-intensity focused ultrasound (LIFUS) is a non-invasive neuromodulation technique that can precisely target deep brain regions. This study aims to evaluate the efficacy, safety, and tolerability of LIFUS targeting the left dorsolateral prefrontal cortex (DLPFC) for preventive treatment of chronic migraine in adults.

This is a randomized, single-blind, sham-controlled clinical trial. Eligible participants with chronic migraine will be randomly assigned to receive either active LIFUS stimulation targeting the left DLPFC or sham stimulation. Participants will receive 10 stimulation sessions over 2 weeks and will be followed for 3 months after intervention.

The primary outcome is the change in monthly migraine days from baseline to 1 month after intervention. Secondary and exploratory outcomes include headache-related disability, quality of life, psychological assessments, electrophysiological measurements, neuroimaging changes, and safety outcomes.

03

Conditions studied

  • Chronic Migraine Headache

Browse trials for

Keywords

  • Migraine
  • Chronic Migraine
  • Low-Intensity Focused Ultrasound
  • Focused Ultrasound Neuromodulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), with a history of migraine for at least 12 months before screening.
  • Migraine onset at or before 50 years of age.
  • During the 3 months before screening, participants have headache occurring on at least 15 days per month, with migraine features or migraine-specific treatment on at least 8 days per month.
  • During the baseline prospective electronic headache diary period, participants record at least 8 migraine days and 15 to 27 headache days.
  • Participants are able to comply with electronic headache diary recording requirements, with data recorded for at least 24 of the 28 days during the screening period.
  • Age between 18 and 65 years at screening visit.
  • Participants are willing and able to provide written and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, brain tumor, or traumatic brain injury.
  • History of transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy within the past 3 months.
  • Presence of MRI-incompatible metallic implants, including but not limited to vascular stents, cardiac pacemakers, or ventriculoperitoneal shunts.
  • comorbid chronic pain conditions, such as fibromyalgia, chronic low back pain, or complex regional pain syndrome.
  • Diagnosis of acute or active temporomandibular disorder.
  • History or diagnosis of other primary headache disorders, including chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or atypical migraine subtypes.
  • Use of opioid-containing analgesics for more than 4 days within 1 month before baseline or during baseline period.
  • Use of any migraine preventive medication within 1 month prior to screening.
  • Use of devices or surgical interventions for migraine treatment within 1 month before baseline, including transcranial magnetic stimulation, greater occipital nerve block, or invasive/non-invasive neuromodulation procedures.
  • History of malignant tumors within the past 5 years, except adequately treated localized basal cell carcinoma or carcinoma in situ of the cervix.
  • History of severe psychiatric disorders, including schizophrenia, other psychotic disorders, bipolar disorder, obsessive-compulsive disorder, or post-traumatic stress disorder.
  • Severe anxiety, depression, or manic symptoms according to predefined scale thresholds (SAS, SDS, and BRMS).
  • Significant risk of self-harm or harm to others based on the Columbia Suicide Severity Rating Scale (C-SSRS) assessment or investigator judgment.
  • History of myocardial infarction, stroke, , unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months before screening.
  • Pregnancy or breastfeeding.
  • Claustrophobia or inability to undergo MRI examination.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    DLPFC-LIFUS

    Device: Low-Intensity Focused Ultrasound Stimulation

  • Sham comparator
    DLPFC-Sham

    Device: Sham Low-Intensity Focused Ultrasound Stimulation

Interventions

  • DeviceLow-Intensity Focused Ultrasound Stimulation

    Participants receive active low-intensity focused ultrasound stimulation targeting the left dorsolateral prefrontal cortex (DLPFC) for preventive treatment of chronic migraine.

  • DeviceSham Low-Intensity Focused Ultrasound Stimulation

    Participants undergo sham stimulation procedures with identical positioning, coupling, and treatment duration as the active stimulation group, but without effective ultrasound output.

06

What researchers measure

Primary outcomes

  1. Change in Monthly Migraine Days

    Change in monthly migraine days from baseline after intervention.

    Time frame: Baseline and 1 month after intervention

Secondary outcomes

  1. Change in Acute Headache Medication Days

    Change in the number of days using acute headache medications from baseline to 1 month after intervention.

    Time frame: Baseline and 1 month after intervention

  2. 50% Responder Rate Based on Monthly Migraine Days

    Proportion of participants achieving at least 50% reduction in monthly migraine days compared with baseline.

    Time frame: 1 month after intervention

  3. 75% Responder Rate Based on Monthly Migraine Days

    Proportion of participants achieving at least 75% reduction in monthly migraine days compared with baseline.

    Time frame: 1 month after intervention

  4. Change in Moderate/Severe Headache Days

    Change in the number of moderate or severe headache days from baseline to 1 month after intervention.

    Time frame: Baseline and 1 month after intervention

  5. Change in Visual Analog Scale (VAS) Score for Headache Intensity

    Headache intensity is assessed using the Visual Analog Scale (VAS). Scores range from 0 to 10, with higher scores indicating greater headache intensity.

    Time frame: Immediately after each intervention session to 1 month after intervention

  6. Change in Most Bothersome Migraine Symptom (MBS) Improvement Score

    Participants identify their most bothersome migraine-associated symptom at baseline from nausea, vomiting, photophobia, or phonophobia. The same symptom is assessed during follow-up using a 7-point patient-reported improvement scale ranging from very much improved to very much worse.

    Time frame: Immediately after intervention and 1 month after intervention

  7. Change in monthly Migraine Disability Assessment (mMIDAS) Score

    The monthly Migraine Disability Assessment (mMIDAS) questionnaire assesses migraine-related disability during the previous month. Higher scores indicate greater migraine-related disability.

    Time frame: Baseline, immediately after intervention, and 1 month after intervention

  8. Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score

    Time frame: Baseline, immediately after intervention, and 1 month after intervention

  9. Change in Headache Impact Test-6 (HIT-6) Score

    The 6-item Headache Impact Test (HIT-6) assesses the impact of headache on daily functioning. Total scores range from 36 to 78, with higher scores indicating greater headache impact.

    Time frame: Baseline, immediately after intervention, and 1 month after intervention

  10. Patient Global Impression of Change (PGI-C) Score

    The Patient Global Impression of Change (PGI-C) is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with higher scores indicating less favorable perceived change.

    Time frame: Immediately after intervention and 1 month after intervention

  11. Change in Generalized Anxiety Disorder 7-item (GAD-7) Score

    The Generalized Anxiety Disorder 7-item (GAD-7) scale assesses anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

    Time frame: Baseline, immediately after intervention, and 1 month after intervention

  12. Change in Patient Health Questionnaire-9 (PHQ-9) Score

    The Patient Health Questionnaire-9 (PHQ-9) assesses depressive symptoms. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

    Time frame: Baseline, immediately after intervention, and 1 month after intervention

  13. Incidence of Adverse Events

    Number and proportion of participants who experience one or more adverse events during the study. All observed and spontaneously reported adverse events will be recorded regardless of their relationship to the study intervention; severity and relatedness will also be assessed.

    Time frame: From baseline through completion of the 3-month follow-up visit

  14. Number of Participants with New Abnormal Findings on T2-Weighted MRI

    Number of participants with new brain parenchymal signal abnormalities, hemorrhage, or edema identified on T2-weighted MRI within 24 hours after the final intervention compared with baseline.

    Time frame: Baseline and within 24 hours after the final intervention session

Other outcomes

  1. Long-term Change in Monthly Acute Headache Medication Days

    Change in the number of days using acute headache medications compared with baseline during extended follow-up

    Time frame: 2 and 3 months after intervention

  2. Long-term Migraine Responder Rate (≥50%)

    Proportion of participants achieving at least 50% reduction in monthly migraine days compared with baseline during extended follow-up.

    Time frame: 2 and 3 months after intervention

  3. Long-term Change in Moderate/Severe Headache Days

    Change in monthly moderate/severe headache days compared with baseline during extended follow-up.

    Time frame: 2 and 3 months after intervention

  4. Long-term Change in Migraine Disability (mMIDAS)

    Change in monthly Migraine Disability Assessment (mMIDAS) score compared with baseline during extended follow-up.

    Time frame: 2 and 3 months after intervention

  5. Long-term Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score

    Change in migraine-specific quality of life assessed using the MSQ v2.1 questionnaire compared with baseline during extended follow-up.

    Time frame: 2 and 3 months after intervention

  6. Long-term Change in Headache Impact Test-6 (HIT-6) Score

    Change in headache-related impact assessed using the HIT-6 questionnaire compared with baseline during extended follow-up.

    Time frame: 2 and 3 months after intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 14 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Oct 5, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Apr 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857109
Responsible party
Zhao Dong, MD (Professor, Chinese PLA General Hospital) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Zhao Dong, Doctor
Contact
dong_zhaozhao@126.com
(+86) 18910685535
Mingjie Zhang, Doctor
Contact
mjzhangnk@163.com
(+86) 18910276582

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion